The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kawano, Mahiru ^a   Mabuchi, Seiji ^a   Matsumoto, Yuri ^a   Sasano, Tomoyuki ^a   Takahashi, Ryoko ^a   Kuroda, Hiromasa ^a   Kozasa, Katsumi ^a   Hashimoto, Kae ^a   Isobe, Aki ^a   Sawada, Kenjiro ^a   Hamasaki, Toshimitsu ^a   Morii, Eiichi ^a   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM;

ANIMAL; BONE MARROW CELL; CELL PROLIFERATION; DISEASE MODEL; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MORTALITY; MOUSE; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE COLONY-STIMULATING FACTOR; MICE; MYELOID CELLS; PLATINUM; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 84950106245     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18217     Document Type: Article

References (35)

1. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J Clin 65, 87-108, doi: 10.3322/caac.21262 (2015).
2. Eifel, P. J. et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 22, 872-880, doi: 10.1200/JCO.2004.07.197 (2004).
3. Kitagawa, R. et al. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol Oncol 125, 307-311, doi: 10.1016/j.ygyno.2012.02.009 (2012).
4. Monk, B. J., Huang, H. Q., Cella, D. and Long, H. J. and Study, G. O. G. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23, 4617-4625, doi: 10.1200/JCO.2005.10.522 (2005).
5. Granger, J. M. and Kontoyiannis, D. P. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer 115, 3919-3923, doi: 10.1002/cncr.24480 (2009).
6. Mabuchi, S. et al. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecol Oncol 122, 25-32, doi: 10.1016/j.ygyno.2011.03.037 (2011).
7. Mabuchi, S. et al. Elevated white blood cell count at the time of recurrence diagnosis is an indicator of short survival in patients with recurrent cervical cancer. Int J Gynecol Cancer 22, 1545-1551, doi: 10.1097/IGC.0b013e31826ea0eb (2012).
8. Wilcox, R. A. Cancer-associated myeloproliferation: old association, new therapeutic target. Mayo Clin Proc 85, 656-663, doi: 10.4065/mcp.2010.0077 (2010).
9. Shojaei, F. et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 106, 6742-6747, doi: 10.1073/pnas.0902280106 (2009).
10. Kowanetz, M. et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+ Ly6C+ granulocytes. Proc Natl Acad Sci USA 107, 21248-21255, doi: 10.1073/pnas.1015855107 (2010).
11. Mabuchi, S. et al. Uterine cervical cancer displaying tumor-related leukocytosis: a distinct clinical entity with radioresistant feature. J Natl Cancer Inst 106, doi: 10.1093/jnci/dju147 (2014).
12. Cortez-Retamozo, V. et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA 109, 2491-2496, doi: 10.1073/pnas.1113744109 (2012).
13. Sakamoto, C. et al. Antiapoptotic effect of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and cyclic AMP on human neutrophils: protein synthesis-dependent and protein synthesis-independent mechanisms and the role of the Janus kinase-STAT pathway. Int J Hematol 77, 60-70 (2003).
14. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62, doi: 10.1126/science.1104819 (2005).
15. Tewari, K. S. et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370, 734-743, doi: 10.1056/NEJMoa1309748 (2014).
16. Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831, doi: 10.1038/nature06348 (2007).
17. Matsumoto, Y., Mabuchi, S., Muraji, M., Morii, E. and Kimura, T. Squamous cell carcinoma of the uterine cervix producing granulocyte colony-stimulating factor: a report of 4 cases and a review of the literature. Int J Gynecol Cancer 20, 417-421, doi: 10.1111/IGC.0b013e3181d15a11 (2010).
18. Gabrilovich, D. I. and Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162-174, doi: 10.1038/nri2506 (2009).
19. Srivastava, M. K. et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 7, e40677, doi: 10.1371/journal.pone.0040677 (2012).
20. Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58, 49-59, doi: 10.1007/s00262- 008-0523-4 (2009).
21. Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A. and Middleton, G. W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60, 1419-1430, doi: 10.1007/s00262-011-1028-0 (2011).
22. Filipazzi, P., Huber, V. and Rivoltini, L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 61, 255-263, doi: 10.1007/s00262-011-1161-9 (2012).
23. Lechner, M. G., Liebertz, D. J. and Epstein, A. L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 185, 2273-2284, doi: 10.4049/jimmunol.1000901 (2010).
24. Lechner, M. G. et al. Functional characterization of human Cd33 + and Cd11b + myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 9, 90, doi: 10.1186/1479-5876-9-90 (2011).
25. Kriz, J. et al. Radiotherapy of splenomegaly : a palliative treatment option for a benign phenomenon in malignant diseases. Strahlenther Onkol 187, 221-224, doi: 10.1007/s00066-011-2252-4 (2011).
26. Hossain, F. et al. Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res, doi: 10.1158/2326-6066.CIR-15-0036 (2015).
27. Leath, C. A. and Straughn, J. M. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol 129, 251-257, doi: 10.1016/j.ygyno.2012.12.035 (2013).
28. Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R. and Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11, 6713-6721, doi: 10.1158/1078-0432.CCR-05-0883 (2005).
29. Ozao-Choy, J. et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69, 2514-2522, doi: 10.1158/0008-5472.CAN-08-4709 (2009).
30. Ko, J. S. et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15, 2148-2157, doi: 10.1158/1078-0432.CCR-08-1332 (2009).
31. Stone, S. C., Rossetti, R. A., Lima, A. M. and Lepique, A. P. HPV associated tumor cells control tumor microenvironment and leukocytosis in experimental models. Immun Inflamm Dis 2, 63-75, doi: 10.1002/iid3.21 (2014).
32. Kasymjanova, G., Kreisman, H., Correa, J. A., Dajczman, E. and Small, D. Does granulocyte colony-stimulating factor affect survival in patients with advanced non-small cell lung cancer? J Thorac Oncol 1, 564-570 (2006).
33. Stehman, F. B., Brady, M. F., Thigpen, J. T., Rossi, E. C. and Burger, R. A. Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 127, 495-501, doi: 10.1016/j.ygyno.2012.09.002 (2012).
34. Yoshida, Y. et al. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum Gene Ther 9, 2503-2515, doi: 10.1089/hum.1998.9.17-2503 (1998).
35. Samulski, R. J., Srivastava, A., Berns, K. I. and Muzyczka, N. Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell 33, 135-143 (1983).